Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (January 2026)
22 slides from Adma Biologics's investor presentation, Jan 12, 2026
Slide 1: Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”), including, without limitati
Slide 3: Who We Are
Who We Are NASDAQ: ADMA
Slide 4: Who We Are: An Innovative, U.S.-Based Specialty Biologics Company
Who We Are: An Innovative, U.S.-Based Specialty Biologics Company ADMA Biologics ian end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty biologics for the prevention and treatment of infectious diseases in the immune compromised and other pa
Slide 5: Vertically Integrated U.S.-Based Manufacturing Supply Chain with Innovative Technology
Vertically Integrated U.S.-Based Manufacturing Supply Chain with Innovative Technology ADMA’s end-to-end manufacturing capabilities enable efficiency, visibility and a competitive advantage Among an elite group of US-based biologic drug manufacturers World-class, cGMP facility for fractionation & pu
Slide 6: Vertical Integration: Plasma Collection Centers are Essential to Ensure Raw Material Supply
Vertical Integration: Plasma Collection Centers are Essentialto Ensure Raw Material Supply to Produce IG 10 FDA-Approved BioCenters in Maryland, Tennessee, Louisiana, North Carolina, South Carolina and Georgia ADMA BioCenters collects hyperimmune & normal source plasma – allows for internal control
Slide 7: US IG Landscape
US IG Landscape NASDAQ: ADMA
Slide 8: Fast Growing & Highest Margin Company in a Large and Expanding IG Market
Fast Growing & Highest Margin Company in a Large and Expanding IG Market (1) Source: Marketing Research Bureau, 2024 U.S. Fractionation Market Report, ADMA internal analysis (2) Rider NL et al. J Allergy Clin Immunol. 2024;153(6):1704-1710 In a 40-year study of 473 patients with PI on standard IVIG3
Slide 9: ASCENIV – ADMA's Unique IG Offering
ASCENIVTM – ADMA’s Unique IG Offering THE PRODUCTION OF ASCENIV ONLY IG PRODUCT MANUFACTURED USING PATENTED DONOR SCREENINGAND PLASMA POOLING METHODS (1) IN A 1-YEAR STUDY OF PATIENTS WITH PI, ASCENIV reported zero serious bacterial infections (SBIs)* *SBIs were defined as a rate of <1.0 cases of ba
Slide 10: ASCENIV – Making a Positive Difference for Patients with PI
ASCENIVTM – Making a Positive Difference for Patients with PI We do what we do because patients are counting on us 1. ADMA Biologics patents issued 9,107,906 – 9,714,283 – 9,815,886 2. ASCENIV Prescribing Information, ADMA Biologics, 2019 Compelling Real-World Patient Testimonials Testimonial Highli
Slide 11: High Demand & Growth Opportunity for ASCENIV Within the Broader IG Market
High Demand & Growth Opportunity for ASCENIV Within the Broader IG Market Significant upside potential with incremental penetration into the complex PI patient TAM Immune Deficient Foundation Source: ADMA Company Estimates (TAM): TOTAL ADDRESSABLE MARKET ~10% (25K PATIENTS) 250,000 DIAGNOSED PI PATI
Slide 12: Established distribution network and channel partners cover targeted call-points
Established distribution network and channel partners comprehensively cover targeted call-points and sites of care Distribution channel is well defined Inpatients – hospital based Outpatients – infusion center / physician office / homecare Established distribution partners handle cold-chain products
Slide 13: Upside & Growth Opportunities
Upside & Growth Opportunities NASDAQ: ADMA
Slide 14: FDA Approved Production Yield Enhancement
FDA approval 1H2025 Successfully commenced commercial scale production using the enhanced yield process FDA Lot Release of First Yield-Enhanced Production Batches FY 2026 expected to be first full year of yield enhanced revenue 20%+ additional IG production yields from same quantities of starting pl
Slide 15: SG-001: Potential Upside Through New Product Pipeline Program
SG-001: Potential Upside Through New Product Pipeline Program Issued IP for commercial product to screen hyperimmunedonors, tailor compositions and form plasma pools. IP protectionthrough 2035 Attractive new product and label expansion opportunities for specialty IGs targeting patient populations wi
Slide 16: Senior Leadership
Senior Leadership NASDAQ: ADMA
Slide 17: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors NAME SELECTED CURRENT OR PAST AFFILIATIONS Dr. Jerrold GrossmanFounder & Vice Chairman Lawrence GuiheenDirector Steven ElmsChairman Young Kwon, Ph.D.Director Alison FingerDirector Kaitlin KestenbergCOO & SVP Compliance Brad TadeCFO & Treasurer Adam
Slide 18: Financials
Financials “— ee NASDAQ: ADMA
Slide 19: Rapidly growing revenue and earnings growth, with uniquely durable asset base
Rapidly growing revenue and earnings growth, with uniquely durable asset base 2025 forecasted Adjusted EBITDA marginsof ~46% 2026 forecasted Adjusted EBITDA marginsof ~57% 2027 forecasted Adjusted EBITDA marginsof ~59% Estimated ‘25-’29 Revenue CAGR (3) of ~20% and Adj. EBITDA CAGR of ~30% Significa
Slide 20: Financial Overview
Financial Overview Financial Overview $ Three Months Ended September 30, 2025 (Unaudited) Three Months Ended September 30, 2024 (Unaudited) Revenues $134.2M $119.8M Gross Profit $75.6M $59.7M Adjusted EBITDA(1) $58.7M $45.4M Adjusted Net Income(2) $38.9M $35.9M Cash and cash equivalents $61.4M $86.7
Slide 21: Commitment to Stockholder Returns
Commitment to Stockholder Returns Ongoing share repurchase program with up to $500mm authorized; continued optimization of capital structure following ‘25 bank-syndicated debt refinancing, reducing ADMA’s Cost of Capital US-Based, End-to-End Controlled Supply Chain 2026 poised to be first full year
Slide 22: Appendix - Non-GAAP Reconciliation
Appendix - Non-GAAP Reconciliation (In US Millions) 3Q25 2Q25 1Q25 4Q24 3Q24 2Q24 1Q24 4Q23 3Q23 2Q23 1Q23 GAAP Net Income (Loss) $36.43 $34.22 $26.90 $111.90 $35.90 $32.10 $17.80 ($17.60) $2.60 ($6.40) ($6.80) Loss on extinguishment of debt $2.18 $1.16 $1.24 $26.20 IT systems disruption $2.80 Defer
Adma Biologics — Investor Presentation (January 2026) on 6ix